Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
We have cloned a member of the steroid hormone receptor superfamily of ligand-activated transcription factors. The receptor homologue is activated by a diverse class of rodent hepatocarcinogens that causes proliferation of peroxisomes. Identification of a peroxisome proliferator-activated receptor should help elucidate the mechanism of the hypolipidaemic effect of these hepatocarcinogens and aid evaluation of their potential carcinogenic risk to man.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“After the structure of PPAR was clarified, three PPAR isoforms (PPARα, PPARγ, and PPARδ) have been identified, each of which is encoded by a separate gene [21].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [21]
Citations
Cites
Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase
Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn, G. T., Mullis, K. B., & Erlich, H. A. (1988) · Science · doi:10.1126/science.2448875 · Cited by 17,719
The Steroid and Thyroid Hormone Receptor Superfamily
Evans, R. M. (1988) · Science · doi:10.1126/science.3283939 · Cited by 7,439
An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs
Kozak, M. (1987) · Nucleic Acids Research · doi:10.1093/nar/15.20.8125 · Cited by 5,087
Gene regulation by steroid hormones
Beato, M. (1989) · Cell · doi:10.1016/0092-8674(89)90237-7 · Cited by 3,383
Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A
Green, S., Walter, P., Kumar, V., Krust, A., Bornert, J.-M., Argos, P., & Chambon, P. (1986) · Nature · doi:10.1038/320134a0 · Cited by 2,321
Self-citationA human retinoic acid receptor which belongs to the family of nuclear receptors
Petkovich, M., Brand, N. J., Krust, A., & Chambon, P. (1987) · Nature · doi:10.1038/330444a0 · Cited by 2,214
Identification of a receptor for the morphogen retinoic acid
Giguere, V., Ong, E. S., Segui, P., & Evans, R. M. (1987) · Nature · doi:10.1038/330624a0 · Cited by 1,965
Primary structure and expression of a functional human glucocorticoid receptor cDNA
Hollenberg, S. M., Weinberger, C., Ong, E. S., Cerelli, G., Oro, A., Lebo, R., Brad Thompson, E., Rosenfeld, M. G., & Evans, R. M. (1985) · Nature · doi:10.1038/318635a0 · Cited by 1,869
The c-erb-A gene encodes a thyroid hormone receptor
Weinberger, C., Thompson, C. C., Ong, E. S., Lebo, R., Gruol, D. J., & Evans, R. M. (1986) · Nature · doi:10.1038/324641a0 · Cited by 1,477
Functional domains of the human estrogen receptor
Kumar, V., Green, S., Stack, G., Berry, M., Jin, J.-R., & Chambon, P. (1987) · Cell · doi:10.1016/0092-8674(87)90581-2 · Cited by 1,316
Self-citation
Research works printed but not linked: 8
- Reddy, J. K., Rao, M. S., Azarnoff, D. I. & Sell, S. Cancer Res. 39, 152–161 (1979).
- Sirtori, C. R., Catapano, A. & Paoletti, R. Atherosclerosis Rev. 2, 113–153 (1977).
- Warren, J. R., Simmon, V. F. & Reddy, J. K. Cancer Res. 40, 36–41 (1980).
- Kasai, H., Okadi, Y., Nishimura, S., Rao, M. S. & Reddy, J. K. Cancer Res. 49, 2603–2605 (1989).
- Marsman, D. S., Cattley, R. C., Conway, J. G. & Popp, J. A. Cancer Res. 48, 6739–6744 (1988).
- Cattley, R. C. & Popp, J. A. Cancer Res. 49, 3246–3251 (1989).
- Nemali, M. R. et al. Cancer Res. 48, 5316–5324 (1988).
- Current Protocols in Molecular Biology (Wiley, New York, 1990).
Cited by
Items 701–800 of 1,011
Chao, P., Chao, C., Lin, F., & Huang, C.-J. (2001) · Journal of Nutrition · doi:10.1093/jn/131.12.3166 · Cited by 114
RAR/RXR and PPAR/RXR signaling in neurological and psychiatric diseases
van Neerven, S., Kampmann, E., & Mey, J. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.04.006 · Cited by 110
“The first PPAR was discovered, cloned and sequenced in 1990, and it was named after its property to be activated by drugs that cause proliferation of peroxisomes in hepatocytes (Issemann and Green, 1990).”
Zhao, M., Liu, Y., Wang, X., New, L., Han, J., & Brunk, U. T. (2002) · APMIS · doi:10.1034/j.1600-0463.2002.100604.x · Cited by 101
“Initially, PPAR were discovered as mediators of peroxisome proliferation induced by hypolipidemic drugs of the fibrate class (17).”
BackgroundPGC-1α sparks the fire of neuroprotection against neurodegenerative disorders
Lv, J., Jiang, S., Yang, Z. P., Hu, W., Wang, Z., Li, T. X., & Yang, Y. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.03.004 · Cited by 105
Park, J., Zarnegar, R., Kanauchi, H., Wong, M. G., Hyun, W. C., Ginzinger, D. G., Lobo, M., Cotter, P. D., Duh, Q., & Clark, O. H. (2005) · Thyroid · doi:10.1089/thy.2005.15.222 · Cited by 102
L-764406 Is a Partial Agonist of Human Peroxisome Proliferator-activated Receptor γ
Elbrecht, A., Chen, Y., Adams, A., Berger, J., Griffin, P., Klatt, T., Zhang, B., Menke, J., Zhou, G., Smith, R. G., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.7913 · Cited by 102
PPARδ Functions as a Prostacyclin Receptor in Blastocyst Implantation
Lim, H. J., & Dey, S. K. (2000) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(00)00243-5 · Cited by 108
Shi, G. Q., Dropinski, J. F., Zhang, Y., Santini, C., Sahoo, S. P., Berger, J. P., MacNaul, K. L., Zhou, G., Agrawal, A. K., Alvaro, R. F., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050373g · Cited by 110
Chen, Y., Lin, S., Chen, Y., Liu, P., & Chen, J. (2006) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/187152906779010737 · Cited by 103
Jain, S. R., Pulikuri, S., Zhu, Y., Qi, C., Kanwar, Y. S., Yeldandi, A. V., Rao, M. S., & Reddy, J. K. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65577-0 · Cited by 110
Nuñez, S. B., Medin, J. A., Braissant, O., Kemp, L., Wahli, W., Ozato, K., & Segars, J. H. (1997) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(96)03980-9 · Cited by 101
Woodyatt, N. J., Lambe, K. G., Myers, K. A., Tugwood, J. D., & Roberts, R. A. (1999) · Carcinogenesis · doi:10.1093/carcin/20.3.369 · Cited by 108
“mPPARα ( 7 ) and mRXRα (a gift from Pierre Chambon) were subcloned into pcDNA3 for use in the reporter gene assays as described previously (24).”
BackgroundMethodVaranasi, U., Chu, R., Chu, S., Espinosa, R., LeBeau, M. M., & Reddy, J. K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3107 · Cited by 98
Hummasti, S., & Tontonoz, P. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0025 · Cited by 97
Labelle, M., Belley, M. L., Gareau, Y., GAUTHIER, J. Y., Guay, D., Gordon, R., Grossman, S. G., Jones, T. R., LEBLANC, Y., McAuliffe, M., et al. (1995) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(95)00023-m · Cited by 100
Oh, E. Y., Min, K. M., Chung, J. H., Min, Y., Lee, M., Kim, K., & Lee, M.-K. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.5.6499 · Cited by 121
Takeuchi, S., Matsuda, T., Kobayashi, S., Takahashi, T., & Kojima, H. (2006) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.08.011 · Cited by 106
PPAR-α effects on the heart and other vascular tissues
Francis, G. A., Annicotte, J.-S., & Auwerx, J. (2003) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01118.2002 · Cited by 100
“The receptor activated by clofibrate and several other “peroxisome proliferating” agents was subsequently cloned and given the name peroxisome proliferator activated receptor alpha (PPARα) (41).”
Inoue, I., Noji, S., Awata, T., Takahashi, K., Nakajima, T., Sonoda, M., Komoda, T., & Katayama, S. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00249-5 · Cited by 100
Miyata, K. S., Zhang, B., Marcus, S. L., Capone, J. P., & Rachubinski, R. A. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36491-9 · Cited by 101
Lu, I.-L., Huang, C.-F., Peng, Y., Lin, Y., Hsieh, H., Chen, C., Lien, T., Lee, H., Mahindroo, N., Prakash, E., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051129s · Cited by 107
Yamazaki, K., Shimizu, M., Okuno, M., Matsushima-Nishiwaki, R., Kanemura, N., Araki, H., Tsurumi, H., Kojima, S., Weinstein, I. B., & Moriwaki, H. (2007) · Gut · doi:10.1136/gut.2007.129858 · Cited by 99
Pesant, M., Sueur, S., Dutartre, P., TALLANDIER, M., Grimaldi, P. A., Rochette, L., & Connat, J. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.10.019 · Cited by 99
“receptors [ 8 ,9]. Three subtypes have been described, including PPARa, g and h/y or y (also called NR1C1, NR1C3 and NUC-1, respectively).”
BackgroundGardner, O., Dewar, B. J., & Graves, L. M. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.012260 · Cited by 110
“1A), a superfamily that also includes receptors for estrogen, progesterone, vitamin D3, and thyroid hormone among others (Evans, 1988; Issemann and Green, 1990).”
BackgroundCentral role of PPARα in the mechanism of action of hepatocarcinogenic peroxisome proliferators
Corton, J. C., Lapinskas, P. J., & Gonzalez, F. J. (2000) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(99)00232-8 · Cited by 107
Robinson, G., Most, D., Ferguson, L. B., Mayfield, J., Harris, R. A., & Blednov, Y. A. (2014) · International Review of Neurobiology · doi:10.1016/b978-0-12-801284-0.00002-6 · Cited by 96
ZHANG, G., ZHANG, L., & DUFF, G. W. (1997) · DNA and Cell Biology · doi:10.1089/dna.1997.16.145 · Cited by 85
Expression of peroxisome proliferator-activated receptors in zebrafish (Danio rerio)
Ibabe, A., Grabenbauer, M., Baumgart‐Vogt, E., Fahimi, D. H., & Cajaraville, M. P. (2002) · Histochemistry and Cell Biology · doi:10.1007/s00418-002-0434-y · Cited by 114
“In 1990 Issemann and Green found a receptor activated by peroxisome proliferators when screening a mouse liver cDNA library ( Issemann and Green 1990 ).”
BackgroundApo A-IV: an update on regulation and physiologic functions
Stan, S., DELVIN, E. E., Lambert, M. A., Seidman, E. G., & Levy, E. H. (2003) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(03)00004-0 · Cited by 105
Sundvold, H., Brzozowska, A., & Lien, S. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7564 · Cited by 108
Rusyn, I., Asakura, S., Pachkowski, B., Bradford, B. U., Denissenko, M. F., Peters, J. M., Holland, S. M., Reddy, J. K., Cunningham, M. L., & Swenberg, J. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3027 · Cited by 97
“Peroxisome proliferation is dependent on activation of PPAR , a nuclear receptor (39), and PPAR -null mice are resistant to phenotypic effects of peroxisome proliferators, such as cell proliferation and liver cancer (40).”
BackgroundRoles of Peroxisome Proliferator-Activated Receptor β/δ in skeletal muscle physiology
Manickam, R., & Wahli, W. (2016) · Biochimie · doi:10.1016/j.biochi.2016.11.010 · Cited by 116
“Posttranslational modificati ons such as phosphorylation, SUMOylation, and ubiquitination, and specific protein-protein in teractions also participate in these regulatory mechanisms [20-26].”
BackgroundBeier, K., Völkl, A., & Fahimi, H. D. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00805-3 · Cited by 98
Akiyama, T. E., Lambert, G., Nicol, C. J., Matsusue, K., Peters, J. M., Brewer, H. B., & Gonzalez, F. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312802200 · Cited by 97
Kippenberger, S., Grundmann-Kollmann, M., Simon, S., Dang, T., Hardt‐Weinelt, K., Kaufmann, R., Bernd, A., & Loitsch, S. M. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2001.01537.x · Cited by 100
Keller, H., Devchand, P. R., Perroud, M., & Wahli, W. (1997) · Biological Chemistry · doi:10.1515/bchm.1997.378.7.651 · Cited by 98
The Effects of Peroxisome Proliferators on Protein Abundances in Mouse Liver
Anderson, N. L., Esquer‐Blasco, R., Richardson, F. C., FOXWORTHY, P. S., & Eacho, P. I. (1996) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1996.0059 · Cited by 97
Chu, R., Madison, L. D., Lin, Y., Kopp, P. A., Rao, M. S. R., Jameson, J. L., & Reddy, J. K. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11593 · Cited by 97
Thakur, J. K., Arthanari, H., Yang, F., Chau, K. H., Wagner, G., & Näär, A. M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808263200 · Cited by 96
Peroxisomal regulation of energy homeostasis: Effect on obesity and related metabolic disorders
Kleiboeker, B. A., & Lodhi, I. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101577 · Cited by 105
“As the name suggests, PPARg belongs to a family of nuclear receptors originally identified based on their ability to be activated by agents that promote peroxisome proliferation [92].”
BackgroundMaldve, R. E., Kim, Y., Muga, S. J., & Fischer, S. M. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32029-0 · Cited by 96
WY14,643, a PPARα Ligand, Has Profound Effects on Immune Responses In Vivo
Cunard, R., DiCampli, D., Archer, D. C., Stevenson, J. L., Ricote, M., Glass, C. K., & Kelly, C. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.12.6806 · Cited by 96
“P eroxisome proliferator-activated receptors (PPARs) 4 are ligand-activated transcription factors that regulate a large number of diverse genes by transcriptional activation and repression (1, 2).”
BackgroundNakshatri, H., & Bhat‐Nakshatri, P. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.10.2491 · Cited by 102
Nuclear Receptors in Bone Physiology and Diseases
Imai, Y., Youn, M.-Y., Inoue, K., Takada, I., Kouzmenko, A., & Kato, S. (2013) · Physiological Reviews · doi:10.1152/physrev.00008.2012 · Cited by 88
Stöckel, B., König, J., Nies, A. T., Cui, Y., Brom, M., & KEPPLER, D. O. R. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01106.x · Cited by 113
PPAR gamma, bioactive lipids, and cancer progression
Gregory, T. (2011) · Frontiers in bioscience · doi:10.2741/4021 · Cited by 96
“The name derives from the fact that the first identified member, mPPAR, was observed to respond to a group of hepatocarcinogens that up-regulate the proliferation of peroxisomes (1).”
BackgroundCurrent advances in Phellinus sensu lato: medicinal species, functions, metabolites and mechanisms
Dai, Y., Zhou, L., Cui, B., Chen, Y., & Decock, C. (2010) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-010-2711-3 · Cited by 95
“Peroxisome proliferator-activated receptor γ (PPAR-γ) is a regulator of glucose homeostasis, and PPAR-γ agonists have potential in the treatment of diabetes ( Issemann and Green 1990; Murphy and Holder 2000).”
BackgroundBRONNER, M., HERTZ, R., & BAR-TANA, J. (2004) · Biochemical Journal · doi:10.1042/bj20040955 · Cited by 90
The Role of PPARγ in Cardiovascular Diseases
Kvandová, M., Majzúnová, M., & Dovinová, I. (2016) · Physiological Research · doi:10.33549/physiolres.933439 · Cited by 103
“The name of this group of nuclear receptors was derived from their ability to stimulate proliferation of peroxisomes in rats (Issemann and Green 1990).”
BackgroundPeroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis
Vosper, H., Khoudoli, G. A., Graham, T. L., & Palmer, C. N. A. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00232-2 · Cited by 104
Börchers, T., & Spener, F. (1994) · Current topics in membranes · doi:10.1016/s0070-2161(08)60984-3 · Cited by 95
Green, S. (1993) · Nature · doi:10.1038/361590a0 · Cited by 95
Self-citationLiver receptor homolog-1, an emerging metabolic modulator
Lee, Y., & Moore, D. D. (2008) · Frontiers in bioscience · doi:10.2741/3128 · Cited by 98
“20 years ago, many former orphan receptors have been associated with physiologic ligands, including the peroxisome proliferator-activated receptors (PPARs) (1, 2), the liver X receptor (LXR) (3, 4) and farnesoid X receptor (FXR) (5-7).”
BackgroundThiazolidinediones and PPAR orchestra as antidiabetic agents: From past to present
Yasmin, S., & Jayaprakash, V. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.020 · Cited by 98
Characterization of the Human Cytochrome P4502D6 Promoter
Cairns, W., Smith, C. D., McLaren, A. W., & Wolf, C. R. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.41.25269 · Cited by 94
Muangmoonchai, R., Smirlis, D., Wong, S. C., Edwards, M., Phillips, I. R., & Shephard, E. A. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3550071 · Cited by 101
Boulanger, J. J., & Messier, C. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.03.063 · Cited by 111
“Peroxisome proliferator-activated receptors (PPARs) belong to the superfamily of nuclear receptors for thyroid hormones (Issemann and Green, 1990).”
Gao, Q., Jia, Y., Yang, G., Zhang, X., Boddu, P. C., Petersen, B., Narsingam, S., Zhu, Y.-J., Thimmapaya, B., Kanwar, Y. S., et al. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.01.018 · Cited by 93
“Activation of lipid-sensing nuclear receptor PPARa in liver promotes the uptake, use, and catabolism of fatty acids by transcriptional up-regulation of genes involved in these physiological processes.(8,16,33,41) In liver, PPARa plays a central role in the regulation of energy burning by peroxisomal and mitochondrial…”
BackgroundInteractions between Host PPARs and Gut Microbiota in Health and Disease
Hasan, A. U., Rahman, A., & Kobori, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020387 · Cited by 101
“PPARα was the first member identified in the early 1990s, as a target of hypolipidemic fibrate [14].”
BackgroundAubert, G., Vega, R. B., & Kelly, D. P. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.08.015 · Cited by 101
“Peroxisome proliferator-activated receptors (PPARs) are members of the extended nuclear hormone receptor family [20,21].”
BackgroundLatini, G., Scoditti, E., Verrotti, A., De Felice, C., & Massaro, M. (2008) · PPAR Research · doi:10.1155/2008/359267 · Cited by 88
“Since the discovery of PPARs in 1990 [17], several functions have been attributed to these receptors.”
BackgroundMajdalawieh, A., & Ro, H.-S. (2010) · Nuclear Receptor Signaling · doi:10.1621/nrs.08004 · Cited by 90
“PPARα, the first PPAR to be identified, is expressed in many tissues and cells including the liver, kidney, skeletal muscle, heart, brown adipose tissue, monocytes, endothelial cells, and vascular smooth muscle cells [Braissant et al., 1996; Issemann and Green, 1990].”
BackgroundRecent findings concerning thiazolidinediones in the treatment of diabetes
Boden, G., & Zhang, M. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.3.243 · Cited by 92
“In 1990, Isseman and Green [2] identified the first nuclear peroxisome proliferator-activated receptor (PPAR)-α. Subsequently, two other PPAR isoforms, PPAR-γ and -δ (also called PPAR-β), were identified [3].”
BackgroundSØYLAND, E., LEA, T., SANDSTAD, B., & DREVON, A. (1994) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1994.tb01080.x · Cited by 93
Kauffmann, H.-M., & Schrenk, D. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8340 · Cited by 93
Fatal Pneumococcal Pneumonia Attributed to Macrolide Resistanceand Azithromycin Monotherapy
WATERER, G. W., Wunderink, R. G., & Jones, C. B. (2000) · CHEST Journal · doi:10.1378/chest.118.6.1839-a · Cited by 93
The role of polyunsaturated fatty acids and GPR40 receptor in brain
Khan, M. Z., & He, L. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.05.013 · Cited by 101
“They are known as PPARα (NR1C1), PPARβ (NR1C2) also named PPARδ, and PPARγ (NR1C3) (Dreyer et al., 1992 ; Issemann and Green, 1990) and each have distinct expression patterns, tissue distribution and physiological functions (Heneka and Landreth, 2007 ; Moreno et al., 2004).”
BackgroundBezafibrate is a dual ligand for PPARα and PPARβ: studies using null mice
Peters, J. M., Aoyama, T., Burns, A., & Gonzalez, F. J. (2003) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(03)00065-9 · Cited by 100
“PPARh (also referred to as PPARy) and PPARg were independently cloned [1–8].”
BackgroundViswakarma, N., Yu, S., Naik, S., Kashireddy, P., Matsumoto, K., Sarkar, J., Surapureddi, S., Jia, Y., Rao, M. S., & Reddy, J. K. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701983200 · Cited by 90
Huang, T.-Y., Zheng, D., Houmard, J. A., Brault, J. J., Hickner, R. C., & Cortright, R. N. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00331.2016 · Cited by 90
Angeli, V., Hammad, H., Staels, B., Capron, M., Lambrecht, B. N., & Trottein, F. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.5295 · Cited by 90
Yen, S. S. C., & Laughlin, G. A. (1998) · Experimental Gerontology · doi:10.1016/s0531-5565(98)00046-1 · Cited by 98
Qi, C., Zhu, Y., Pan, J., Usuda, N., Maeda, N., Yeldandi, A. V., Rao, M. S., Hashimoto, T., & Reddy, J. K. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.22.15775 · Cited by 92
Murakami, K., Ide, T., Suzuki, M., Mochizuki, T., & Kadowaki, T. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0951 · Cited by 105
RXR Agonists Activate PPARα-Inducible Genes, Lower Triglycerides, and Raise HDL Levels In Vivo
Mukherjee, R., Strasser, J., Jow, L., Hoener, P., Paterniti, J. R., & Heyman, R. A. (1998) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.18.2.272 · Cited by 89
Systems biology at the Institute for Systems Biology
Hood, L., Rowen, L., Galas, D. J., & Aitchison, J. D. (2008) · Briefings in Functional Genomics and Proteomics · doi:10.1093/bfgp/eln027 · Cited by 96
“the level of transcription [14–26].”
Functional significance of the two ACOX1 isoforms and their crosstalks with PPARα and RXRα
Vluggens, A., Andreoletti, P., Viswakarma, N., Jia, Y., Matsumoto, K., Kulik, W., Khan, M., Huang, J., Guo, D., Yu, S., et al. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.46 · Cited by 94
“4 At the transcriptional level, PPAR α , which forms a heterodimer with retinoid X receptor (RXR)”
BackgroundPeroxisome Proliferators‐Activated Receptor (PPAR) Modulators and Metabolic Disorders
Cho, M.-C., Lee, K., Paik, S.-G., & Yoon, D.-Y. (2008) · PPAR Research · doi:10.1155/2008/679137 · Cited by 89
“PPARα was first cloned from the rodent liver in 1990 [41], and PPARβ and PPARγ were first identified in Xenopus [42].”
BackgroundPeroxisome Proliferators and Peroxisome Proliferator-Activated Receptor α
Reddy, J. K. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63787-x · Cited by 105
Einerhand, A. W. C., Kos, W., Distel, B., & Tabak, H. F. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17927.x · Cited by 91
Bilbao, E., Raingeard, D., de Cerio, O. D., Ortiz‐Zarragoitia, M., Ruiz, P., Izagirre, U., Orbea, A., Marigómez, I., Cajaraville, M. P., & Cancio, I. (2010) · Aquatic Toxicology · doi:10.1016/j.aquatox.2010.02.018 · Cited by 91
Drukała, J., Urbańska, K., Wilk, A. M., Grabacka, M., Wybieralska, E., Valle, L. D., Madeja, Z., & Reiss, K. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-159 · Cited by 97
“Fenofibrate is a specific agonist of PPARα, which belongs to the family of steroid hormone nuclear receptors [20], and is characterized by relatively low systemic toxicity [13,14].”
BackgroundCrisóstomo, L., Alves, M. G., Gorga, A., Sousa, M., Riera, M. F., Galardo, M. N., Meroni, S. B., & Oliveira, P. F. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7698-0_11 · Cited by 102
Whitfield, G. K., Hsieh, J., Nakajima, S., MacDonald, P. N., Thompson, P. D., Jurutka, P. W., Haussler, C. A., & Haussler, M. R. (1995) · Molecular Endocrinology · doi:10.1210/mend.9.9.7491109 · Cited by 90
Peroxisome Proliferator‐Activated Receptors and Lipid Metabolisma
KELLER, H., Mahfoudi, A., Dreyer, C., Hihi, A. K., Medin, J. A., Ozato, K., & Wahli, W. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb32279.x · Cited by 90
Guyton, K. Z., Chiu, W. A., Bateson, T. F., Jinot, J., Scott, C. S., Brown, R. C., & Caldwell, J. C. (2009) · Environmental Health Perspectives · doi:10.1289/ehp.0900758 · Cited by 88
“The evidential support included the in vitro demonstration of receptor activation by its monoester metabolite [mono-2-ethylhexyl phthalate (MEHP)] (Issemann and Green 1990; Maloney and Waxman 1999).”
BackgroundFenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice
Carmona, M. C., Louche, K., Nibbelink, M. M., Prunet‐Marcassus, B., Bross, A., Desbazeille, M., Dacquet, C., Renard, P., Casteilla, L., & Pénicaud, L. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0802943 · Cited by 89
Polvani, S., Tarocchi, M., Tempesti, S., Bencini, L., & Galli, A. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i8.2441 · Cited by 95
Finstad, H. S., Drevon, C. A., Kulseth, M. A., Synstad, A. V., Knudsen, E., & Kolset, S. O. (1998) · Biochemical Journal · doi:10.1042/bj3360451 · Cited by 103
Andersen, Ø., Eijsink, V. G. H., & Thomassen, M. S. (2000) · Gene · doi:10.1016/s0378-1119(00)00350-4 · Cited by 106
Camp, H. S., Chaudhry, A., & Leff, T. (2001) · Endocrinology · doi:10.1210/endo.142.7.8254 · Cited by 87
Matsuura, H., Adachi, H., Smart, R. C., Xu, X., Arata, J., & Jetten, A. M. (1999) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(98)00214-7 · Cited by 99
Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancer
Fenner, M. H., & Elstner, E. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.557 · Cited by 88
“PPAR-α was cloned as the main molecular target of peroxisome proliferators in 1990 [9].”
Phthalate exposure and prostate cancer in a population-based nested case-control study
Chuang, S., Chen, H., Sun, C.-W., Chen, Y.-A., Wang, Y.-H., Chiang, C., Chen, C., Wang, S., Chen, C., & Hsiung, C. A. (2019) · Environmental Research · doi:10.1016/j.envres.2019.108902 · Cited by 91
Ligand-dependent interaction of hepatic fatty acid-binding protein with the nucleus
Lawrence, J. W., Kroll, D. J., & Eacho, P. I. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33451-9 · Cited by 90
Prostacyclin signaling in the kidney: implications for health and disease
Nasrallah, R., & Hébert, R. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00454.2004 · Cited by 94
“Since the cloning of PPAR in 1990 (61), there has been an enormous body of research implicating these transcription factors in various cellular events: metabolism, differentiation, growth, apoptosis, tumorigenesis, etc.”
BackgroundIntegrative and Systemic Approaches for Evaluating PPARβ/δ (PPARD) Function
Attianese, G. M. G., & Desvergne, B. (2015) · Nuclear Receptor Signaling · doi:10.1621/nrs.13001 · Cited by 83
“…involved in the peroxisome proliferation response to some chemicals in mice, which was accordingly referred to as peroxisome-proliferator activated receptor (PPAR) [Issemann and Green, 1990], three PPAR genes, α (PPARA), β (PPARD) and γ (PPARG), were identified in Xenopus laevi [Krey et al., 1993].”
BackgroundAnticancer Properties of Fenofibrate: A Repurposing Use
Lian, X., Wang, G., Zhou, H., Zheng, Z., Fu, Y., & Cai, L. (2018) · Journal of Cancer · doi:10.7150/jca.24488 · Cited by 92
“This leads to the activation of target gene transcription, including that of lipid metabolism regulation genes [25, 26].”
BackgroundTherapeutic potential of thiazolidinediones as anticancer agents
Panigrahy, D., Shen, L. Q., Kieran, M. W., & Kaipainen, A. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.12.1925 · Cited by 92
“In 1990, Isseman and Green identified the first PPAR, mouse PPAR-α , as a nuclear hormone receptor activated by peroxisome proliferators [7].”
BackgroundJohnson, T. E., Holloway, M. K., Vogel, R., Rutledge, S. J., Perkins, J. J., Rodan, G. A., & Schmidt, A. (1997) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(97)00064-2 · Cited by 93
Metadata
- Authors
- Issemann, I., & Green, S.
- Venue
- Nature
- Published
- 1990-10
- Volume
- 347
- Issue
- 6294
- Pages
- 645-650
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2066092624
- Cited by
- 3,519
- References
- 56
- Citations by year
- 2026: 38 · 2025: 59 · 2024: 60 · 2023: 47 · 2022: 58 · 2021: 71 · 2020: 63 · 2019: 82 · 2018: 74 · 2017: 90 · 2016: 87 · 2015: 94 · 2014: 98 · 2013: 106 · 2012: 133
- FWCI
- 25.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- peroxisome proliferator-activated receptors, steroid hormone receptors, ligand-activated transcription factors, peroxisome proliferation, hepatocarcinogens, hypolipidemic effect, cancer risk, receptor cloning
- MeSH terms
- Amino Acid Sequence, Animals, Hypolipidemic Agents, Base Sequence, Binding Sites, Cloning, Molecular, DNA, Humans, Liver, Liver Neoplasms, Experimental, Microbodies, Molecular Sequence Data, Nafenopin, Receptors, Estrogen, Receptors, Glucocorticoid, Receptors, Steroid, Sequence Homology, Nucleic Acid, Tissue Distribution, Gene Expression, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.